Medispan ⁤Recognized for Technological Prowess and Innovation in Joint Development of Immune Booster

Medispan, a domestic bio venture, has been ⁣recognized for its technological prowess and innovation through the joint ​development⁤ of an immune booster with the U.S. National Institute of Allergy and Infectious Diseases‍ (NIAID).

The company was selected ⁣for the ‘TIPS Startup Commercialization and Overseas Marketing Support Project’ hosted by⁢ the Ministry ‍of SMEs and Startups, in⁢ recognition of its achievements. The ‍TIPS⁤ program is ‍a representative startup fostering program that supports private-led technology startups.

With this selection, Medispan will receive up to 200 million won in additional ​funding for startup commercialization and⁣ overseas marketing. This ⁤funding will be used for technology development for efficacy evaluation and mechanism research on aging and various geriatric diseases.

A company official stated, “This selection has once again proven Medispan’s active international joint research and development ​achievements.” Medispan ‌was ‍the first overseas company to be invited to a seminar hosted by⁢ NIAID, introducing its technology to the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), the Bill Gates Foundation, and vaccine development officials in the United ​States.

Medispan has signed a material transfer agreement (MTA) with Duke University, Stanford University, and the University of California, in the U.S. to develop large-scale immune enhancers that can improve the efficacy of⁤ infectious disease vaccines, anticancer drugs, allergies, etc., led by⁤ the‌ NIAID. The company has also completed drug delivery for large-scale evaluation of the substances.

Kyung-ah Cho, CEO of Medispan, stated, ‌”We are jointly developing MSP-102 with ‌our partners in the United States and preparing to enter the global market through NIAID’s clinical support program.”⁣ Cho continued, “MSP-102 is a next-generation nasal‌ immune ⁤enhancer‌ targeting aging and infectious diseases, and⁤ we are currently conducting development and mechanism elucidation research⁣ with‍ Stanford University Professor Bali Plendran.”

CEO ‌Cho expressed his​ aspirations, saying, “The government is currently preparing various support projects for aging-related research and securing global competitiveness. We will proceed with the development of MSP-102 in‍ cooperation with domestic and foreign partners and successfully enter the global market through NIAID’s clinical​ support program.”

Key Points:

• Medispan selected⁢ for the ‘TIPS Startup Commercialization and Overseas Marketing Support Project’ ⁢hosted​ by the Ministry of SMEs and Startups.
• Company to receive up to 200​ million won in additional funding​ for startup commercialization and overseas marketing.
• Medispan jointly developing MSP-102 ⁢with partners in the United States and preparing to enter the global market through NIAID’s clinical support program.